Failure to meet USFDA compliance can endanger Indian pharma companies' US generics business, new report warns

A new report from Motilal Oswal notes that increasingly Indian pharma companies are finding it hard to meet the compliance criteria set by USFDA, leading to regulatory hurdles for the US generics market.

Related Keywords

United States ,India ,Halol ,Gujarat ,Tushar Manudhane ,Sumit Gupta ,Glenmark Pharma Baddi ,Motilal Oswal ,Sun Pharmaceutical Industries ,Biocon ,Boehringer Ingelheim ,Drug Administration ,Motilal Oswal Financial Services ,United States Food ,Official Action Indication ,Glenmark Pharma ,Torrent Pharma ,Ulcerative Colitis ,Usfda ,Indian Pharma Companies ,S Market ,